TCGA-52-7812-01A-11R-2125-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.610
- MYC_TARGETS_V1+0.580
- INTERFERON_ALPHA_RESPONSE+0.570
- MYC_TARGETS_V2+0.570
- INTERFERON_GAMMA_RESPONSE+0.550
- G2M_CHECKPOINT+0.540
- DNA_REPAIR+0.490
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.490
- MTORC1_SIGNALING+0.420
- ALLOGRAFT_REJECTION+0.400
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.430
- WNT_BETA_CATENIN_SIGNALING-0.390
- KRAS_SIGNALING_DN-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- MYOGENESIS-0.300
- CHOLESTEROL_HOMEOSTASIS-0.200
- COAGULATION-0.200
- BILE_ACID_METABOLISM-0.170
- PANCREAS_BETA_CELLS-0.170
- ANGIOGENESIS-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-73-4666-01A-01R-1206-07 | — | cohortA1 | 0.893 |
| 2 | TCGA-FD-A3B6-01A-21R-A20F-07 | — | — | 0.892 |
| 3 | TCGA-38-4625-01A-01R-1206-07 | — | cohortA1 | 0.889 |
| 4 | SRR650153 | — | — | 0.888 |
| 5 | TCGA-4Z-AA81-01A-11R-A39I-07 | — | — | 0.886 |
| 6 | TCGA-PQ-A6FI-01A-11R-A31N-07 | — | — | 0.885 |
| 7 | TCGA-XF-AAN2-01A-11R-A42T-07 | — | — | 0.878 |
| 8 | 1e0f16e6-de1c-4d1e-b1f6-5fabbea1591b | — | — | 0.875 |
| 9 | C3N-00203 | — | cohortA1 | 0.873 |
| 10 | TCGA-ZF-A9RF-01A-11R-A38B-07 | — | — | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.610 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.580 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.550 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.490 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.490 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |